General - Press Releases

Date	Title	Company
13-Apr-2023	OPM annonce ses résultats annuels 2022 et fait le point sur ses développements cliniques	Businesswire
13-Apr-2023	OPM Announces Its 2022 Annual Results and Provides an Update on Its Clinical Developments	Businesswire
13-Apr-2023	Number of Shares and Voting Rights of ADOCIA as of March 31st, 2023	Businesswire
13-Apr-2023	SpineGuard Announces Its Full-year 2022 Financial Results and Its First Quarter 2023 Sales	Businesswire
13-Apr-2023	IPS HEART receives FDA Rare Pediatric Drug Designations for both of its Stem Cell Drugs for Duchenne Muscular Dystrophy	Businesswire
13-Apr-2023	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Wheels Up Experience Inc. (UP) on Behalf of Investors	Businesswire
13-Apr-2023	2023 Sweet Biopharma Day Winner is Epitopea!	Businesswire
13-Apr-2023	Benoit Larose Named BIOQuébec’s Executive Director	Businesswire
13-Apr-2023	Wellington Management Announces Close of Biomedical Innovation II	Businesswire
13-Apr-2023	Model N Announces Date of Second Quarter Fiscal Year 2023 Financial Results	Businesswire
13-Apr-2023	Pharmaceutical Multinationals Continue To Spurn The Opportunity To Connect Via Social Media At A Local Level	Businesswire
13-Apr-2023	Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial	Businesswire
13-Apr-2023	Genefic’s Watson Rx Solutions Earns Prestigious NABP Merchant Accreditation	Businesswire
13-Apr-2023	Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference	Businesswire
13-Apr-2023	BeiGene Expands Presence in Latin America With Opening of Brazil Office	Businesswire
13-Apr-2023	Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical Trials for the Treatment of Geographic Atrophy from Macular Degeneration	Businesswire
13-Apr-2023	Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease	Businesswire
13-Apr-2023	Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis	Businesswire
13-Apr-2023	FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Businesswire
13-Apr-2023	Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting	Businesswire